SCHEMBL3666064

SCHEMBL3666064

CS(=O)(=O)NC(=O)C1CCN(c2ccc(N)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
KDM4E B2RXH2 4/20 0.44
LMNA P02545 3/20 0.44
ABL1 P00519 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
SMO Q99835 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 2/20 0.40
TDO2 P48775 1/20 0.40
MAPT P10636 1/20 0.40
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA4 P22748 3/20 0.40
CA7 P43166 3/20 0.40
CA9 Q16790 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3815470 0.81 GFER (0.47) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL3544514 0.79 LMNA (0.55) KMT2AKDM4ELMNAABL1L3MBTL1
SCHEMBL594954 0.79 LMNA (0.67) KMT2AALDH1A1KDM4ELMNAABL1
SCHEMBL22770920 0.79 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL23086790 0.77 KDM4E (0.41) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL5459880 0.76 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL596004 0.75 KDM4E (0.51) KMT2AMEN1KDM4ELMNAABL1
SCHEMBL13009560 0.74 KDM4E (0.48) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL595334 0.74 SHMT2 (0.59) KMT2AALDH1A1L3MBTL1POLBMAPT
SCHEMBL15651714 0.74 LMNA (0.56) KMT2AKDM4ELMNAABL1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155687-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-02-24 EP disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed
WO-2008141976-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885MEN1 3549/4885ALDH1A1 573/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885MEN1 3549/4885ALDH1A1 573/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885MEN1 3549/4885ALDH1A1 573/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885MEN1 3549/4885ALDH1A1 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.